Protalix BioTherapeutics (NYSE:PLX) Given New $15.00 Price Target at HC Wainwright

Protalix BioTherapeutics (NYSE:PLX) had its target price hoisted by HC Wainwright from $10.00 to $15.00 in a report published on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2024 earnings at $0.06 EPS, FY2024 earnings at $0.01 EPS, Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.06 EPS and FY2025 earnings at $0.19 EPS.

Separately, StockNews.com downgraded Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, January 24th.

Protalix BioTherapeutics Price Performance

Shares of PLX stock opened at $2.67 on Monday. The company has a market capitalization of $196.59 million, a P/E ratio of -20.54 and a beta of 0.75. The company’s 50-day simple moving average is $2.01 and its two-hundred day simple moving average is $1.43. Protalix BioTherapeutics has a one year low of $0.82 and a one year high of $2.71.

Hedge Funds Weigh In On Protalix BioTherapeutics

Several institutional investors have recently bought and sold shares of the business. Y Intercept Hong Kong Ltd purchased a new position in shares of Protalix BioTherapeutics in the 4th quarter valued at $35,000. PFG Investments LLC purchased a new position in Protalix BioTherapeutics in the fourth quarter valued at about $39,000. Sanctuary Advisors LLC bought a new position in Protalix BioTherapeutics in the third quarter worth about $38,000. Virtu Financial LLC purchased a new stake in shares of Protalix BioTherapeutics during the third quarter valued at about $44,000. Finally, XTX Topco Ltd purchased a new stake in shares of Protalix BioTherapeutics during the third quarter valued at about $36,000. 16.53% of the stock is owned by hedge funds and other institutional investors.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.